ArticleCancer reports (Hoboken, N.J.)2026
Does Curative Radiotherapy Impact Fatigue Onset in Prostate Cancer Patients? An Analysis of 1253 Patients.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study investigates the impact of radiotherapy (RT) on fatigue levels in prostate cancer (PC) patients, considering the significant physical and psychological impact of fatigue associated with cancer and its treatments.
methodsPC patients undergoing a radical treatment from December 2002 to September 2022 were retrospectively evaluated. Fatigue was assessed using the Cancer Linear Analogue Scale (CLAS) across three dimensions: wellbeing (CLAS1), energy level (CLAS2), and daily activity performance (CLAS3), measured at baseline (T0), 1 month (T1), and 12 months (T2) post-RT. Changes in CLAS scores ≥ 2 points from T0 were deemed clinically significant for RT-induced fatigue.
resultsThe cohort consisted of 1253 patients, with a median age of 72 years (range 45-90). Approximately 30% of patients experienced moderate or high levels of fatigue at baseline. At T1, RT-related fatigue onset (decrease of CLAS1, 2, and 3 values) was observed in 10.8%, 14.3%, and 14.8% of patients, respectively. These figures slightly increased at T2 (12.7%, 18.8%, and 19.4%, respectively). Logistic regression identified hypofractionated RT, ADT, surgery, alcohol consumption, and higher-grade toxicities as predictors of worsened fatigue across various dimensions.
conclusionIn this extensive cohort of PC patients, approximately 30% experienced moderate to severe fatigue before initiating RT, with less than 20% reporting new or exacerbated fatigue post-treatment. Factors including treatment-related toxicities, hypofractionation, alcohol use, and ADT were significant contributors to fatigue. These findings underscore the complexity of managing fatigue in PC, highlighting the influence of both treatment modalities and lifestyle factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.